Page last updated: 2024-11-07

2-dodecenoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

2-dodecenoic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

trans-2-dodecenoic acid : The trans isomer of 2-dodecenoic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

2-dodecenoic acid : A dodecenoic acid having its double bond at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5282729
CHEMBL ID4281333
CHEBI ID38371
CHEBI ID37162
MeSH IDM0519721

Synonyms (49)

Synonym
(2e)-2-dodecenoic acid
dodec-2-enoic acid
2-dodecensaeure
c12:1
dodec-2-ensaeure
CHEBI:38371
CHEBI:37162
trans-2-dodecenoic acid
2t-dodecensaeure
(e)-2-dodecenoic acid
12:1, n-10 trans
c12:1, n-10 trans
(2e)-dodec-2-enoic acid
trans-2-lauroleic acid
dodecen-(2t)-saeure
trans-dodec-2-enoic acid
2-dodecenoic acid
4412-16-2
c12:1n-10
2e-dodecenoic acid
LMFA01030788
2e-lauroleic acid
(e)-dodec-2-enoic acid
EN300-65552
AKOS008105134
A826494
einecs 224-569-1
nsc 59856
ai3-11152
1289-45-8
32466-54-9
trans-2-dodecenoicacid
PAWGRNGPMLVJQH-ZHACJKMWSA-N
3x1 ,
mfcd00045906
AS-57983
Q27117632
Q27117056
AMY37907
W16764
WS-00320
CHEMBL4281333
CS-0152270
A934942
dodec-2-enoicacid
D5660
DTXSID401343611
EN300-365600
Z336127680
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
2-dodecenoic acidA dodecenoic acid having its double bond at position 2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Fatty Acid Biosynthesis233

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1417295Inhibition of electric eel AChE at 10 M using acetylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition and measured at 1 min intervals for 30 mins by Ellman's method2018Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20
Unexpected AChE inhibitory activity of (2E)α,β-unsaturated fatty acids.
AID1575239Stimulation of human 20S proteasome at 25 uM using 11 amino acid FRET peptide as substrate measured every 2 mins over 1 hr by FRET assay relative to control2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Analysis of chain length, substitution patterns, and unsaturation of AM-404 derivatives as 20S proteasome stimulators.
AID1417297Inhibition of equine serum BuChE at 10 M using butyrylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition and measured at 1 min intervals for 30 mins by Ellman's method2018Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20
Unexpected AChE inhibitory activity of (2E)α,β-unsaturated fatty acids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.57)18.7374
1990's0 (0.00)18.2507
2000's3 (10.71)29.6817
2010's22 (78.57)24.3611
2020's2 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]